Somatostatin receptor scintigraphy in the follow-up of myasthenia gravis

Basit Öğe Kaydı
dc.authorwosidKornblum, Cornelia/IUM-4180-2023
dc.authorwosidEzziddin, Samer/E-8406-2014
dc.contributor.authorGao, Z. R.
dc.contributor.authorKornblum, C.
dc.contributor.authorFlacke, S.
dc.contributor.authorLogvinski, T.
dc.contributor.authorYueksel, M.
dc.contributor.authorAn, R.
dc.contributor.authorKlockgether, T.
dc.date.accessioned2024-06-12T11:08:55Z
dc.date.available2024-06-12T11:08:55Z
dc.date.issued2007
dc.departmentTrakya Üniversitesien_US
dc.description.abstractTo evaluate the potential value of somatostatin receptor scintigraphy (SRS) using In-111-DTPA (diethylenetriaminepenta acetic acid)-D-Phe(1)-octreotide (In-111-pentetreotide) in patients with recurring or persisting symptoms of myasthenia gravis (MG), 14 consecutive cases with such supplemental receptor imaging during neurological routine follow-up were retrospectively evaluated in this study. All 14 patients underwent SRS in addition to chest computed tomography (CT). Mean follow-up after imaging was 34 months. Eight patients had previous thymectomy, and three patients were referred to surgery after scintigraphy and chest CT. SRS was positive in one of the 14 patients with local recurrence of thymoma and pleural invasion, and negative in the remaining 13 patients. CT was positive for thymoma in three patients, inconclusive in four patients and negative in seven patients. In conclusion, while SRS may be able to detect thymoma lesions including metastases, it seems of limited value in patients with inconspicuous CT findings. Our initial experience fails to point out a benefit of SRS in the management of persisting or recurring MG (with regard to detection of thymic disorders) compared to CT. Whether SRS is useful for differentiating thymoma from non-neoplastic thymic disease may be investigated by larger series. A predominant proportion of patients with unsatisfactory treatment response, however, continue to suffer an unfavourable clinical course despite absent evidence for thymic pathology.en_US
dc.identifier.doi10.1007/s10072-007-0816-y
dc.identifier.endpage180en_US
dc.identifier.issn1590-1874
dc.identifier.issn1590-3478
dc.identifier.issue4en_US
dc.identifier.pmid17690847en_US
dc.identifier.scopus2-s2.0-34547951344en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage175en_US
dc.identifier.urihttps://doi.org/10.1007/s10072-007-0816-y
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22600
dc.identifier.volume28en_US
dc.identifier.wosWOS:000248815000006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer-Verlag Italia Srlen_US
dc.relation.ispartofNeurological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMyasthenia Gravisen_US
dc.subjectIndium-111-Pentetreotideen_US
dc.subjectSomatostatin Receptor Scintigraphyen_US
dc.subjectThymomaen_US
dc.subjectPathological Findingsen_US
dc.subjectThymic Disordersen_US
dc.subjectThymectomyen_US
dc.subjectThymomaen_US
dc.subjectPrednisoneen_US
dc.subjectDiagnosisen_US
dc.subjectTherapyen_US
dc.subjectAnalogsen_US
dc.subjectLesionsen_US
dc.subjectTumorsen_US
dc.titleSomatostatin receptor scintigraphy in the follow-up of myasthenia gravisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu